JP2024525797A - 減少したIMiD活性を伴ってBTKを分解するための二官能性化合物 - Google Patents

減少したIMiD活性を伴ってBTKを分解するための二官能性化合物 Download PDF

Info

Publication number
JP2024525797A
JP2024525797A JP2024502035A JP2024502035A JP2024525797A JP 2024525797 A JP2024525797 A JP 2024525797A JP 2024502035 A JP2024502035 A JP 2024502035A JP 2024502035 A JP2024502035 A JP 2024502035A JP 2024525797 A JP2024525797 A JP 2024525797A
Authority
JP
Japan
Prior art keywords
membered
heterocycloalkyl
alkyl
compound
bond
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024502035A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525797A5 (https=
Inventor
グイドッチ,クリスティアーナ
ノヴィスキー,マーク
パワーズ,ジャニーヌ
ラウントリー,ライアン
シオウ タン,イン
Original Assignee
ニューリックス セラピューティクス,インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューリックス セラピューティクス,インコーポレイテッド filed Critical ニューリックス セラピューティクス,インコーポレイテッド
Publication of JP2024525797A publication Critical patent/JP2024525797A/ja
Publication of JP2024525797A5 publication Critical patent/JP2024525797A5/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024502035A 2021-07-14 2022-07-13 減少したIMiD活性を伴ってBTKを分解するための二官能性化合物 Pending JP2024525797A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163221905P 2021-07-14 2021-07-14
US63/221,905 2021-07-14
PCT/US2022/037029 WO2023287928A1 (en) 2021-07-14 2022-07-13 Bifunctional compounds for degrading btk with diminished imid activity

Publications (2)

Publication Number Publication Date
JP2024525797A true JP2024525797A (ja) 2024-07-12
JP2024525797A5 JP2024525797A5 (https=) 2025-07-22

Family

ID=82799901

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024502035A Pending JP2024525797A (ja) 2021-07-14 2022-07-13 減少したIMiD活性を伴ってBTKを分解するための二官能性化合物

Country Status (9)

Country Link
US (1) US20240336595A1 (https=)
EP (1) EP4370123A1 (https=)
JP (1) JP2024525797A (https=)
KR (1) KR20240035837A (https=)
CN (1) CN118019538A (https=)
AU (1) AU2022310182A1 (https=)
CA (1) CA3225367A1 (https=)
IL (1) IL309796A (https=)
WO (1) WO2023287928A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021004191A (es) 2018-10-15 2021-05-27 Nurix Therapeutics Inc Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma.
US12582722B2 (en) 2019-02-13 2026-03-24 Nurix Therapeutics, Inc. Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
WO2021113557A1 (en) 2019-12-04 2021-06-10 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
JP2024524480A (ja) * 2021-07-01 2024-07-05 ハンチョウ、ヘルズン、セラピューティクス、カンパニー、リミテッド ブルトン型チロシンキナーゼ及びその突然変異体の分解剤、組成物並びにそれらの応用
CA3236073A1 (en) 2021-10-26 2023-05-04 Robert J. Brown Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk
WO2025162210A1 (zh) * 2024-02-04 2025-08-07 上海超阳药业有限公司 一种具备降解酪氨酸蛋白激酶btk活性的化合物及其制备方法和用途
WO2026005533A1 (ko) * 2024-06-27 2026-01-02 한미약품 주식회사 신규한 이종이작용기 단백질 분해제 및 이의 용도
CN120590386A (zh) * 2025-05-30 2025-09-05 北京科莱博医药开发有限责任公司 一种喹喔啉类蛋白降解剂及其制备方法和应用
CN120617259B (zh) * 2025-06-05 2026-04-10 南昌大学第一附属医院 Btk protac化合物nx-5948的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021004191A (es) 2018-10-15 2021-05-27 Nurix Therapeutics Inc Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma.
WO2021113557A1 (en) 2019-12-04 2021-06-10 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway

Also Published As

Publication number Publication date
IL309796A (en) 2024-02-01
WO2023287928A1 (en) 2023-01-19
KR20240035837A (ko) 2024-03-18
EP4370123A1 (en) 2024-05-22
AU2022310182A1 (en) 2024-02-01
CN118019538A (zh) 2024-05-10
US20240336595A1 (en) 2024-10-10
CA3225367A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
US12600732B2 (en) Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
JP2024525797A (ja) 減少したIMiD活性を伴ってBTKを分解するための二官能性化合物
US11866442B2 (en) Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
US12582722B2 (en) Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
EP4055019B1 (en) Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
US20230158151A1 (en) Compounds for inhibiting or degrading target proteins, compositions, comprising the same, methods of their making, and methods of their use
JP2024526984A (ja) 増進されたIMiD活性を伴ってBTKを分解するための二官能性化合物
BR122023025072A2 (pt) Usos de compostos bifuncionais para degradar btk por meio da via da ubiquitina-proteossoma
HK40081936A (en) Bifunctional compounds for degrading btk via ubiquitin proteosome pathway

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250711

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250711